2179222-27-4

ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), can be use in the study of primary open angle glaucoma (POAG), and wet age-related macular degeneration.

[1] Pfeiffer N, Voykov B, Renieri G, et al. First-in-human phase I study of ISTH0036, an antisense oligonucleotide selectively targeting transforming growth factor beta 2 (TGF-β2), in subjects with open-angle glaucoma undergoing glaucoma filtration surgery.?PLoS One. 2017;12(11):e0188899. Published 2017 Nov 30. doi:10.1371/journal.pone.0188899 DOI:10.1371/journal.pone.0188899